Home » Topics » BioWorld Science

BioWorld Science
RSS

Olpadronate associated with improvement in osteogenesis imperfecta

Nov. 24, 1997

EntreMed: Q3 1997 highlights

Nov. 24, 1997

Accolate now available in Canada

Nov. 21, 1997

Floxin recommended for FDA approval

Nov. 21, 1997

Allergan files registration statement for new company

Nov. 21, 1997

RIGScan EMEA review delayed

Nov. 21, 1997

Amylin, SIDDCO join forces for metabolic drug discovery

Nov. 21, 1997

Imutec licenses novel anticancer compounds from Ion

Nov. 21, 1997

Update on pagoclone

Nov. 21, 1997

InKine (formerly Panax) completes acquisitions, raises funds for CBP-1011 development

Nov. 21, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.